CHELSEY PHILLIPS: Open Payments
NPI 1356833883 · ZACHARY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,004 in 50 payments from 17 companies in 2025. Trend: 2023 $592 · 2024 $1,279 · 2025 $1,004
Food & beverage: $1,004
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $274 |
| Novo Nordisk Inc | 8 | $220 |
| AstraZeneca Pharmaceuticals LP | 5 | $87 |
| Abbott Laboratories | 3 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| PFIZER INC. | 2 | $44 |
| Lilly USA, LLC | 2 | $36 |
| Amgen Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
Products named: Ozempic, QULIPTA, VRAYLAR, AIRSUPRA, FREESTYLE LIBRE 3, CAPLYTA, ELIQUIS, MOUNJARO.
Industry payments across LA — which companies pay providers there.
